<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03792841</url>
  </required_header>
  <id_info>
    <org_study_id>20180101</org_study_id>
    <nct_id>NCT03792841</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC</brief_title>
  <official_title>A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the safety and tolerability of AMG 160 and in combination with
      pembrolizumab in adult subjects with metastatic castration-resistant prostate cancer (mCRPC),
      and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, first-in-human study to evaluate the safety and tolerability of AMG 160; a
      half-life extended (HLE) bispecific T-cell engager (BiTEÂ®) antibody construct, alone and in
      combination with pembrolizumab in subjects with metastatic castration-resistant prostate
      cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2019</start_date>
  <completion_date type="Anticipated">August 27, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 27, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose-limiting toxicity</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant changes in vital signs</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant changes in electrocardiogram (ECG)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant changes in clinical laboratory tests</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject incidence of changes in pharmacokinetics - maximum serum concentration (Cmax)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response (OR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific antigen (PSA) response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) (radiographic and PSA)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in time to progression (radiographic and PSA)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1, 2 and 3-year overall survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PCWG3-recommended endpoints - time to symptomatic skeletal events</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject incidence of changes in pharmacokinetics - minimum serum concentration (Cmin)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject incidence of changes in pharmacokinetics - area under the concentration-time curve (AUC) over the dosing interval</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject incidence of changes in pharmacokinetics - administration including accumulation following multiple dosing</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject incidence of changes in pharmacokinetics - half-life</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PCWG3-recommended endpoints - lactate dehydrogenase [LDH]</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PCWG3-recommended endpoints - hemoglobin</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PCWG3-recommended endpoints - neutrophil-to-lymphocyte ratio</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PCWG3-recommended endpoints - urine N-telopeptide</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PCWG3-recommended endpoints alkaline phosphatase [total, bone]</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Parts 1, 2, 3 and 4 of the study</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Metastatic Castration-resistant Prostate Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>AMG 160 Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: AMG 160 is administered intravenously at different dose levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 160 + Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2: AMG 160 is administered intravenously at different dose levels. Pembrolizumab will be administered intravenously at a dose of 200 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 160 + Etanercept Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 3: AMG 160 is administered intravenously at RP2D/MTD levels. Etanercept will be administered subcutaneously at a dose of 50 mg in cycle 1 only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 160 Outpatient Center</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 4: AMG 160 is administered intravenously at RP2D/MTD in an oncology outpatient center up to 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 160</intervention_name>
    <description>Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer</description>
    <arm_group_label>AMG 160 + Pembrolizumab</arm_group_label>
    <arm_group_label>AMG 160 Treatment</arm_group_label>
    <other_name>PSMA Targeted Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Combined with AMG 160 for investigational treatment of mCRPC</description>
    <arm_group_label>AMG 160 + Pembrolizumab</arm_group_label>
    <other_name>PD-1 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Prophylaxis for AMG 160-related cytokine release syndrome.</description>
    <arm_group_label>AMG 160 + Etanercept Prophylaxis</arm_group_label>
    <other_name>TNF-alpha inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Outpatient Oncology Center</intervention_name>
    <description>Outpatient administration of AMG 160 for close monitoring of AMG 160-related safety events.</description>
    <arm_group_label>AMG 160 Outpatient Center</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        All Parts

        Inclusion Criteria:

          -  Subject has provided informed consent prior to initiation of any study-specific
             activities/procedures

          -  Subjects with histologically or cytologically confirmed mCRPC who are refractory to a
             novel antiandrogen therapy (abiraterone, enzalutamide, and/or apalutamide) and have
             failed at least 1 (but not more than 2) taxane regimens (or who are deemed medically
             unsuitable to be treated with a taxane regimen or have actively refused treatment with
             a taxane regimen). Progression on novel antiandrogen therapy may have occurred in the
             non-metastatic CRPC setting

          -  Subject should have undergone bilateral orchiectomy or should be on continuous
             androgen-deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH)
             agonist or antagonist

          -  Total serum testosterone &lt;/= 50 ng/dL or 1.7 nmol/L

          -  Evidence of progressive disease, defined as 1 or more PCWG3 criteria: PSA level &gt;/=1
             ng/mL that has increased on at least 2 successive occasions at least 1 week apart,
             nodal or visceral progression as defined by RECIST 1.1 with PCGW3 modifications,
             and/or appearance of 2 or more new lesions in bone scan

        Exclusion Criteria:

          -  Any anticancer therapy or immunotherapy within 4 weeks of start of first dose, not
             including luteinizing hormone-releasing hormone agonist (LHRH)/GnRH analogue
             (agonist/antagonist). Subjects on a stable bisophosphonate or denosumab regimen for
             &gt;/= 30 days prior to randomization are eligible

          -  Prior PSMA-targeted therapy (subjects on prior therapy may be eligible if discussed
             with Amgen medical monitor prior to enrollment)

          -  Central nervous system (CNS) metastases, leptomeningeal disease, or spinal cord
             compression

          -  Active autoimmune disease or any other diseases requiring immunosuppressive therapy
             while on study

          -  Needing chronic systemic corticosteroid therapy (prednisone &gt; 10 mg per day or
             equivalent) or any other immunosuppressive therapies (including anti-tumor necrosis
             factor alpha [TNF alpha] therapies) unless stopped 7 days prior to start of first dose

          -  Myocardial infarction, unstable angina, cardiac arrhythmia requiring medication,
             and/or symptomatic congestive heart failure (New York Heart Association &gt; class II)
             within 12 months of first dose of AMG 160

        Part 2 only:

          -  Subjects on a prior PD-1 or PD-L1 inhibitor who experienced a Grade 3 or higher
             immune-related adverse event prior to first day of dosing

          -  History or evidence of interstitial lung disease or active, non-infectious pneumonitis

        Part 3 only:

        -Evidence of active tuberculosis on chest radiograph within 3 months prior to the first
        dose of investigational product
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 2, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMG 160</keyword>
  <keyword>HLE-BiTEÂ®</keyword>
  <keyword>mCRPC</keyword>
  <keyword>Metastatic Castration-resistant Prostate Cancer</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>PSMA</keyword>
  <keyword>BiTEÂ®</keyword>
  <keyword>Bispecific T-Cell engager</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>Immunooncology</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>PSMA Targeted Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

